| 英文别名 |
Cholestan-3-ol, (3a,5b)-;5ß(H)-Cholestan-3α-ol;Epicoprostanol;EPICOPROSTEROL;5β5BETA-CHOLESTAN-3ALPHA-OL;-Cholestan-3α-ol;Coprostan-3α-ol;epi-Coprostanol;epi-Coprosterol;Epikoprosterin;NSC 18182;α-Coprostanol;NSC18182;(3alpha,5beta)-cholestan-3-ol;(3.alpha.,5.beta.)-Cholestan-3-ol;UFH3K1F9EG;DTXSID7046700;DTXCID5026700;.alpha.-Coprostanol;3-alpha-hydroxy-5beta-cholestanol;LMST04030110;NS00124865;(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol;HY-W127498;CHEBI:171890;Tox21_112538;5.BETA.-EPICHOLESTANOL;UNII-UFH3K1F9EG;CS-0185726;NCGC00167541-01;5.beta.-Cholestan-3.alpha.-ol;5-beta-Cholestan-3-alpha-ol;Cholestan-3-ol, (3.alpha.,5.beta.)-;CAS-516-92-7;Q27291059;CHEMBL1998721;516-92-7;NSC-18182;QYIXCDOBOSTCEI-KKFSNPNRSA-N;MFCD00064143;Epicoprostanol, United States Pharmacopeia (USP) Reference Standard;5beta-Cholestan-3alpha-ol, >=95%;Cholestan-3-ol, (3alpha,5beta)-;Coprostan-3.alpha.-ol;EPICOPROSTANOL [USP-RS];G77765;DB-242217 |